TropiA

TropiA is a biotechnology company dedicated to the discovery and development of novel therapeutics for the treatment of malaria. Spun out from the University of Central Florida, the company focuses on a new class of small molecule inhibitors that target essential biological processes in the malaria parasite, Plasmodium falciparum. Their lead programs aim to address the growing challenge of drug-resistant malaria strains by utilizing unique mechanisms of action distinct from current frontline treatments. TropiA's research is supported by federal grants and academic collaborations, positioning it as an emerging player in the global health and infectious disease space.